MARKET

IBIO

IBIO

IBIO
AMEX

Real-time Quotes | Nasdaq Last Sale

1.610
+0.230
+16.67%
After Hours: 1.580 -0.03 -1.86% 19:59 05/07 EDT
OPEN
1.940
PREV CLOSE
1.380
HIGH
1.950
LOW
1.540
VOLUME
110.41M
TURNOVER
--
52 WEEK HIGH
7.45
52 WEEK LOW
0.9600
MARKET CAP
347.78M
P/E (TTM)
-8.8268
1D
5D
1M
3M
1Y
5Y
DJ IBio Shares Trading Higher After Covid-19 Vaccine Study Results
Dow Jones · 1d ago
Why Is iBio's Stock Trading Higher Today?
iBio, Inc. (NYSE: IBIO) shares are trading higher after the company provided an update on its IBIO-201 program and reported on its progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV...
Benzinga · 1d ago
Mid-Morning Market Update: Markets Open Higher; US Adds Only 266,000 Jobs In April
Following the market opening Friday, the Dow traded up 0.40% to 34,686.06 while the NASDAQ rose 1.16% to 13,790.95. The S&P also rose, gaining 0.69% to 4,230.68.
Benzinga · 1d ago
ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
ChemoCentryx hurt by a series of downgradesLate yesterday, ChemoCentryx (CCXI) announced its narrow win at the FDA’s expert panel meeting on the potential approval for avacopan in the treatment of
Seekingalpha · 2d ago
Thinking about buying stock in iBio, T2 Biosystems, Viewray, GoPro, or Tilray?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IBIO, TTOO, VRAY, GPRO, and TLRY.
PR Newswire - PRF · 2d ago
TLRY, ET, ROKU and NET among premarket gainers
iBio (IBIO) +33% on COVID-19 study update.Orgenesis (ORGS) +11% on Q1 results.Chemomab Therapeutics (CMMB) +12%.T2 Biosystems, Inc. (TTOO) +11% on Q1 results.ViewRay (VRAY) +12%.Epizyme (EPZM) +11% on Q1 results.CureVac N.V. (CVAC) +9%.Roku (ROKU) +9% on
Seekingalpha · 2d ago
iBio Stock Is Trading Higher After Announcing Next-Gen COVID-19 Vaccine Candidate
Benzinga · 2d ago
32 Stocks Moving in Friday's Pre-Market Session
Gainers Assertio Holdings, Inc. (NASDAQ: ASRT) shares rose 44.2% to $0.7190 in pre-market trading after the company reported better-than-expected Q1 results.
Benzinga · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IBIO. Analyze the recent business situations of IBIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IBIO stock price target is 2.500 with a high estimate of 3.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 332.24K
% Owned: 0.15%
Shares Outstanding: 216.01M
TypeInstitutionsShares
Increased
4
14.06K
New
2
19.83K
Decreased
3
6.98K
Sold Out
1
250
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.86%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/President/Chief Executive Officer/Director
Thomas Isett
Chief Financial Officer/Chief Accounting Officer
Robert Lutz
Chief Operating Officer
Randy Maddux
Chief Scientific Officer
Martin Brenner
Treasurer/Secretary/Director
Robert Kay
Independent Director
Linda Armstrong
Independent Director
Glenn Chang
Independent Director
Seymour Flug
Independent Director
James Hill
Independent Director
Alexandra Kropotova
Independent Director
John McKey
Independent Director
Gary Sender
No Data
About IBIO
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.

Webull offers kinds of Ibio Inc stock information, including AMEX:IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.